Estrogen-based hormone therapy in women with primary ovarian insufficiency: a systematic review

Abstract

Purpose Sex hormones play a role in bone density, cardiovascular health and wellbeing throughout reproductive lifespan. Women with primary ovarian insufficiency (POI) have lower estrogen levels requiring hormone therapy (HT) to manage symptoms and to protect against adverse long-term health outcomes. Yet, the effectiveness of HT in preventing adverse outcomes has not been systematically assessed. We summarize the evidence regarding effects of HT on bone and cardiovascular health in women with POI. Methods A comprehensive search of the electronic databases MEDLINE, EMBASE and Scopus was conducted by a medical reference librarian from database inception to January 2016. Randomized trials and observational cohort studies with an estrogen-based HT intervention in women with POI under the age of 40 were included. Reviewers worked independently and in duplicate to assess eligibility and risk of bias, and extract data of interest from each study. Results The search identified 1670 articles; 12 met inclusion criteria. Four randomized clinical trials and 8 cohort studies at high risk of bias enrolled 806 women with POI. The most common HT formulations were transdermal estradiol and oral conjugated equine estrogen combined with medroxyprogesterone acetate. Bone mineral density was the most frequent outcome, with 3 out of 8 studies showing HT associated increase benefits. Only 1 study reported effects on fractures or vasomotor symptoms and none on cardiovascular mortality. Results regarding lipid profiles were inconsistent. Conclusions Evidence supporting bone and cardiovascular benefits of HT in women with POI is limited by high risk of bias, reliance on surrogate outcomes and heterogeneity of trials regarding the formulation, dose, route of administration and regimen of HT. Further research addressing patient important outcomes such as fractures, stroke and cardiovascular mortality are crucial to optimize benefits of this therapy. Registration PROSPERO CRD 4201603616

Hypogonadism in Children with a Previous History of Cancer: Endocrine Management and Follow-Up

“…Sex steroid hormone replacement therapy is indicated in all girls and women age < 40 with hypogonadism, either due to primary gonadal failure or due to hypothalamic-pituitary failure. Estrogen replacement will restore pubertal development and may remediate or prevent the consequences of premature estrogen deficiency such as loss of bone mass, loss of self-esteem and decrease in sexual activity [49]. There is insufficient evidence that androgen replacement therapy in women with POI has beneficial effect on sexual function, bone mineral density, or quality of life [50].…”

Estrogen-induced Tgfbr1 and Bmpr1a Expression Repressed via Estrogen Receptor Beta in MC3T3-E1 Cells

“…Estrogen, a steroid hormone in the human body, plays an important role in many physiological processes,[ 1 ] such as the maintenance of secondary sexual characteristics, the development of neurons, and bone homeostasis. [ 2 ] Estrogen is critical to maintain bone and bone density. [ 3 ] Estrogen deficiency often leads to the emergence of osteoporosis.…”

Severe Phenotype of APECED (APS1) Increases Risk for Structural Bone Alterations

“…The adult patients with APECED were shorter and their BMI was lower than in controls subjects, which may explain partly the differences in bone architecture. Women with POI have increased risk of fractures and osteoporosis, but the current body of evidence of hormone replacement therapy on fracture risk and bone health is limited (23). In women with PAI who have not hypoparathyroidism, postmenopausal state increases the risk of bone loss, and glucocorticoid replacement therapy must be particularly carefully monitored (12).…”